Uwell Biopharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	60.24	43.4	23.09	27.71	49.76
Short-Term Investments	260	4.5	63	-	18
Cash & Short-Term Investments	320.24	47.9	86.09	27.71	67.76
Cash Growth	568.62%	-44.37%	210.70%	-59.11%	89.86%
Other Receivables	0.46	0.04	0.07	0	0.02
Receivables	0.46	0.04	0.07	0	0.02
Prepaid Expenses	0.46	0.46	0.71	0.48	4.32
Other Current Assets	0.1	0.09	0.05	0.27	0.06
Total Current Assets	321.26	48.48	86.91	28.46	72.16
Property, Plant & Equipment	19.53	19.56	25.48	26.6	33.11
Other Intangible Assets	0	0.04	0.09	0.23	0.43
Other Long-Term Assets	8.34	8.08	6.04	5.11	0.58
Total Assets	349.13	76.16	118.51	60.4	106.27
Accrued Expenses	-	5.36	4.42	5.62	5.52
Current Portion of Leases	2.56	4.25	4.14	3.4	4.19
Other Current Liabilities	10.49	1.09	0.49	0.8	1.09
Total Current Liabilities	13.05	10.7	9.05	9.81	10.8
Long-Term Leases	1.69	0.86	3.98	4.95	8.34
Total Liabilities	14.75	11.56	13.03	14.76	19.15
Common Stock	200	117	117	57	251.8
Additional Paid-In Capital	255.48	2.54	47.54	2.54	3.18
Retained Earnings	-121.5	-55.3	-59.43	-14.26	-168.23
Comprehensive Income & Other	0.4	0.38	0.38	0.37	0.37
Shareholders' Equity	334.38	64.61	105.48	45.64	87.13
Total Liabilities & Equity	349.13	76.16	118.51	60.4	106.27
Total Debt	4.26	5.11	8.12	8.34	12.53
Net Cash (Debt)	315.98	42.79	77.98	19.37	55.23
Net Cash Growth	638.50%	-45.13%	302.67%	-64.94%	188.23%
Net Cash Per Share	2.05	0.37	0.88	0.34	2.34
Filing Date Shares Outstanding	190.9	117	117	57	29.2
Total Common Shares Outstanding	190.9	117	117	57	29.2
Working Capital	308.21	37.79	77.86	18.65	61.36
Book Value Per Share	1.75	0.55	0.90	0.80	2.98
Tangible Book Value	334.38	64.57	105.4	45.41	86.7
Tangible Book Value Per Share	1.75	0.55	0.90	0.80	2.97
Machinery	-	16.44	16.44	14.44	14.31
Construction In Progress	-	-	-	-	5.79
Leasehold Improvements	-	9.32	9.32	9.32	3.19

Source: S&P Global Market Intelligence. Standard template. Financial Sources.